May 25, 2017 / 12:20 PM / 3 months ago

BRIEF-Trovagene says Phase 1 safety study supports planned development of PCM-075 in AML

May 25 (Reuters) - Trovagene Inc

* Phase 1 safety study supports planned development of PCM-075 in AML

* Trovagene Inc says data is supportive of phase 1/2 clinical trial in patients with aml and is now being submitted for peer review publication by study investigators Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below